suma/sarcoma

BACKGROUND OF THE INVENTION Paclitaxel therapy has been used to treat Kaposi's sarcoma patients. However, at dosage levels suggested by the prior art, there are unwanted hematological side effects and regression of tumors after cessation of treatment is common. Thus, the prior art suggests that long

RELATED APPLICATIONS This application is a .sctn. 371 national stage application based on Patent Cooperation Treaty Application serial number PCT/GB2015/052943, filed Oct. 8, 2015; which claims the benefit of priority to GB 1417832.1, filed Oct. 8, 2014; and GB 1512279.9, filed Jul. 14, 2015. This

RELATED APPLICATIONS This application is a .sctn. 371 national stage application based on Patent Cooperation Treaty Application serial number PCT/GB2015/052939, filed Oct. 8, 2015; which claims the benefit of priority to GB 1417829.7, filed Oct. 8, 2014; and GB 1511387.1, filed Jun. 29, 2015. This

TECHNICAL FIELD OF THE INVENTION The present invention relates to a novel monoclonal antibody reactive with human carcinoma cells. More particularly, the antibody of the invention is a monoclonal antibody that reacts with a glycolipid cell membrane antigen found on the surface of human carcinomas,

BACKGROUND OF THE INVENTION The present invention relates to the therapeutic application of human chorionic gonadotropin (HCG) for its previously unappreciated, immune-potentiating properties in human patients. More specifically, the present invention relates to the use of HCG in treatment of and

TECHNICAL FIELD This invention is a pharmaceutical composition that is effective against the treatment of viruses. The composition can be used to treat viral infections, notably hepatitis, including hepatitis C virus (HCV) hepatitis B virus (HBV), human immunodeficiency syndrome (HIV), and Kaposi

2. REFERENCE TO SEQUENCE LISTING, TABLE OR COMPUTER PROGRAM The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Nov. 29, 2013, is named ENZ-109(CIP)_SL.txt and

This invention relates to the expression of cyclin G1 in tumors. More particularly, this invention relates to: (i) the treatment of tumors such as osteogenic sarcoma or Ewing's sarcoma, by inhibiting cyclin G1 protein in the tumor cells; (ii) the prevention of restenosis by inhibiting cyclin G1

CROSS REFERENCE TO RELATED APPLICATIONS This application is related to and incorporates by reference the contents of copending applications Ser. Nos. 560,104 and 560,105, filed respectively on Mar. 19, 1975 and Mar. 19, 1975 and entitled DAUNOMYCINS, PROCESS FOR THEIR PREPARATION AND USES THEREOF